Focused On-demand Library for Protein fantom

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q68CZ1

UPID:

FTM_HUMAN

Alternative names:

Nephrocystin-8; RPGR-interacting protein 1-like protein

Alternative UPACC:

Q68CZ1; A0PJ88; Q9Y2K8

Background:

Protein fantom, also known as Nephrocystin-8 and RPGR-interacting protein 1-like protein, plays a crucial role in various cellular processes. It negatively regulates signaling through the G-protein coupled thromboxane A2 receptor and is involved in programmed cell death, craniofacial development, limb patterning, and the formation of the left-right axis. Additionally, it contributes to the organization of apical junctions and the establishment of planar cell polarity, such as in the cochlear sensory epithelium.

Therapeutic significance:

Protein fantom is implicated in several genetic disorders, including Joubert syndrome 7, Meckel syndrome 5, and COACH syndrome 3, all of which involve developmental and structural anomalies. Understanding the role of Protein fantom could open doors to potential therapeutic strategies for these complex conditions, highlighting its significance in medical research and drug discovery.